This is a life-threatening clinical-dermatological emergency that presents with a variety of symptoms and signs, including skin rash (especially of the exanthema type), which may be accompanied by fever, lymphadenomegaly, hepatitis, hematological (especially atypical lymphocytes and eosinophilia), renal, cardiac, pulmonary and pancreatic changes.1 The term DRESS was initially proposed by Bocquet et al., in 1996, in a review article on the drug hypersensitivity syndrome, which had been previously described under several different terms or synonymies, such as dapsone syndrome, anticonvulsant hypersensitivity syndrome, hydantoin syndrome, and allopurinol hypersensitivity syndrome, depending on the pharmacological agent involved, throughout the 20th century.2 The first case description compatible with DRESS was reported by Myers et al., in 1937
Product Overview GLOW BLEND | 70mg (GHK-Cu 50mg, BPC-157 10mg, TB500 10mg) GLOW BLEND offers a multi-compound research reagent formulated strictly for in vitro and animal model studies
Cc bc s cng khuyn co rng, khng nn ung qu 2000mg glutathione mi ngy v khng nn s dng chng trong thi gian di
Research surrounding BPC-157 has focused on its ability to support muscle recovery, connective tissue health, and digestive tissue integrity, making it one of the most widely used peptides in recovery-focused protocols
10.1111/j.1574-6968.2008.01285.x FEMS Microbiol
These benefits provide a system-wide slowing and reversal of certain aging processes as well as prevent disease
